BRAF<sup>wild</sup> papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors.

Kim, Hyeung Kyoo; Lee, Inhwa; Lee, Jeonghun; Chang, Hang-Seok; Soh, Euy Young; Park, Il Seok; Kim, Jin Hwan; Rho, Young Soo et al. · Head Neck · 2018

other · Level V

Where this comes from

Abstract

Using a large set of genomic data from The Cancer Genome Atlas (TCGA), we classified BRAF<sup>wild</sup> papillary thyroid carcinomas (PTCs) into 2 subtypes with distinct molecular patterns and different clinical behaviors. We also suggested gene signatures (RAS-score) to predict molecular subtypes and clinical behaviors of BRAF<sup>wild</sup> PTC. Integrated genomic analysis was done using all genomic data of PTC in TCGA data portal (https://tcga-data.nci.nih.gov) and cancer browser (https://genome-cancer.ucsc.edu). Using Gene Ontology and a logistic regression test, we selected gene signatures (RAS-score) and applied this prediction model to the validation cohort (GSE60542). When we performed multiplatform genomic analysis, BRAF<sup>wild</sup> PTCs were divided into 2 molecular subtypes. Each subtype showed distinct molecular patterns and clinical behaviors. Gene signatures successfully predicted molecular subtype in another validation cohort. We found that BRAF<sup>wild</sup> PTCs were divided into 2 molecular subtypes and each subtype showed distinct molecular patterns, different activated pathways, and different clinical behaviors.

Medical subject headings